ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 778,19
0,47%
Dow Jones
42 175,11
0,00%
DAX
19 449,97
1,20%
Brent Oil
71,015
0,09%
Bitcoin
65 738,52
0,85%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. BeyondSpring Inc (BYSI)

  7. BeyondSpring Inc (BYSI) Actualités

BYSI

BeyondSpring (BYSI)

BeyondSpring Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BYSI
DateHeureSourceTitreSymboleSociété
16/09/202413h00GlobeNewswire Inc.BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024NASDAQ:BYSIBeyondSpring Inc
16/09/202413h00GlobeNewswire Inc.BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024NASDAQ:BYSIBeyondSpring Inc
10/09/202413h00GlobeNewswire Inc.BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory MediciNASDAQ:BYSIBeyondSpring Inc
03/09/202413h00GlobeNewswire Inc.BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, PlinabulinNASDAQ:BYSIBeyondSpring Inc
29/08/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BYSIBeyondSpring Inc
06/08/202413h00GlobeNewswire Inc.SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology IndicationsNASDAQ:BYSIBeyondSpring Inc
15/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BYSIBeyondSpring Inc
12/06/202423h11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BYSIBeyondSpring Inc
12/06/202414h30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BYSIBeyondSpring Inc
16/05/202414h00GlobeNewswire Inc.BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
03/05/202413h00GlobeNewswire Inc.BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsNASDAQ:BYSIBeyondSpring Inc
29/04/202423h30GlobeNewswire Inc.BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsNASDAQ:BYSIBeyondSpring Inc
29/04/202423h30GlobeNewswire Inc.BeyondSpring Files 2023 Annual Report on Form 20-FNASDAQ:BYSIBeyondSpring Inc
25/03/202412h00GlobeNewswire Inc.BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerNASDAQ:BYSIBeyondSpring Inc
26/02/202414h00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing RequirementsNASDAQ:BYSIBeyondSpring Inc
14/02/202422h30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BYSIBeyondSpring Inc
10/01/202421h00GlobeNewswire Inc.BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KNASDAQ:BYSIBeyondSpring Inc
18/12/202322h30GlobeNewswire Inc.BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNASDAQ:BYSIBeyondSpring Inc
07/11/202313h00GlobeNewswire Inc.BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 InhibitorsNASDAQ:BYSIBeyondSpring Inc
31/10/202313h00GlobeNewswire Inc.BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere ModelsNASDAQ:BYSIBeyondSpring Inc
30/10/202313h00GlobeNewswire Inc.BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:BYSIBeyondSpring Inc
26/10/202314h30GlobeNewswire Inc.SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” SymposiumNASDAQ:BYSIBeyondSpring Inc
23/10/202313h45GlobeNewswire Inc.SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of DirectorsNASDAQ:BYSIBeyondSpring Inc
27/09/202316h00GlobeNewswire Inc.BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual MeetingNASDAQ:BYSIBeyondSpring Inc
07/09/202314h00GlobeNewswire Inc.BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare ConferenceNASDAQ:BYSIBeyondSpring Inc
20/06/202314h00GlobeNewswire Inc.SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of DirectorsNASDAQ:BYSIBeyondSpring Inc
07/06/202314h00GlobeNewswire Inc.BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCTNASDAQ:BYSIBeyondSpring Inc
18/05/202314h30GlobeNewswire Inc.BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual MeetingNASDAQ:BYSIBeyondSpring Inc
12/05/202322h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BYSIBeyondSpring Inc
18/04/202322h32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:BYSIBeyondSpring Inc
 Showing the most relevant articles for your search:NASDAQ:BYSI

Dernières Valeurs Consultées

EU
MAU
Maurel Et Prom
TG
75H
Country Garden Services
LSE
RK55
Bank Mont.28
BIT
UB87PR
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés